Curriculum Vitaes
Profile Information
- Affiliation
- Professor, Research Promotion Headquarters, BNCT Research Center, Fujita Health UniversityProfessor, Premium Research Institute for Human Metaverse Medicine, Osaka University
- Degree
- MD(Mar, 1984)Ph.D.(Mar, 1988)
- Researcher number
- 60204533
- J-GLOBAL ID
- 200901003262194571
- researchmap Member ID
- 1000305140
Research Interests
6Research Areas
4Research History
11-
Oct, 2007 - Mar, 2024
-
Apr, 2004 - Sep, 2007
Education
2-
Mar, 1984 - Apr, 1988
-
Apr, 1978 - Mar, 1984
Awards
12-
Jan, 2020
-
2014
-
2013
-
2013
Papers
473-
Nuclear Medicine and Biology, 156-157 109623-109623, May, 2026 Peer-reviewed
-
Journal of proteome research, 25(4) 1878-1891, Apr 3, 2026 Peer-reviewedProteases play crucial roles in numerous biological processes through specific protein cleavage, and their dysregulation has been implicated in various diseases. To better understand protease specificity, we developed a lauroylation-assisted proteomic identification of protease cleavage sites (PICS) workflow that labels and enriches targeted protease-generated neo-N-termini using economical reagents and standard laboratory equipment. The lauroylation enables both discrimination of the neo-N-termini in LC-MS/MS and efficient enrichment on a C18 StageTip by exploiting its hydrophobicity. Among tested acylations, we found lauroylation to be optimal for PICS and improved enrichment and fractionation conditions. We demonstrated that this method can profile specificities of multiple proteases with high sensitivity. Furthermore, we extended this concept to N-terminomics to examine proteolysis at the protein level. Protein N-terminal dimethylation is used for labeling, and tryptic internal peptides are lauroylated for removal. This approach identified over 1500 cleavages induced by etoposide, including 912 Asp-cleaved sites consistent with caspase-3 motifs and sensitive to inhibition by Z-DEVD-FMK. Additionally, 2286 protein N-termini were identified in untreated cells, including 1794 non-ORF N-termini with 665 previously annotated processing sites. These results demonstrate that our workflow provides a simple, economical, and widely applicable method for characterizing protease cleavage at both peptide and protein levels.
-
International Immunopharmacology, 172 116138-116138, Mar, 2026 Peer-reviewed
-
Cancer & Metabolism, 13(1), Dec 2, 2025 Peer-reviewedLast authorCorresponding author
-
Environmental science & technology, Nov 21, 2025 Peer-reviewedBacteria reduce toxic selenium oxyanions, such as selenite, to elemental selenium (Se0), forming selenium nanoparticles (SeNPs) either intracellularly or extracellularly. However, the mechanism through which extracellular SeNPs (Ex-SeNPs) are exported remains unclear. In this study, we characterized Ex-SeNPs biosynthesized by Escherichia coli during the aerobic reduction of selenite. The SeNPs appeared within 2 h of exposure, remained extracellular, and displayed a consistent spherical morphology (∼100 nm). Purified Ex-SeNPs consisted of an Se0 core enveloped by a membrane-like layer containing lipids, proteins, carbohydrates, peptidoglycan, and lipopolysaccharides. Fluorescence microscopy and gas chromatography-mass spectrometry indicated that the encapsulated membrane originates from the E. coli cell membrane. Notably, mutants deficient in the outer membrane proteins OmpC or TolA failed to excrete SeNPs, resulting in intracellular accumulation despite efficient Se0 synthesis. Our findings suggest that E. coli forms SeNPs intracellularly and exports them via an envelope-dependent process, during which the particles may become encapsulated in membrane-like structures. These findings help clarify the mechanism underlying a membrane-dependent pathway for SeNP detoxification and export that had been suggested but not directly demonstrated.
Misc.
440-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 140P-140P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 280P-280P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 24P-24P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 256P-256P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 201P-201P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 258P-258P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 141P-141P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 120P-120P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 281P-281P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 120P-120P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 280P-280P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 140P-140P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 282P-282P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 281P-281P, 2005
-
BREAST CANCER RESEARCH AND TREATMENT, 94 S28-S28, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 283P-283P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 141P-141P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 257P-257P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 281P-281P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 141P-141P, 2005
-
Journal of the Kyorin Medical Society, 35(4) 400-406, Dec 30, 2004Functional characterization of mouse proteins is an essential step for gene-knock out studies. In the preset investigation, we demonstrated functional characterization and immunohistochemical localization of mouse organic anion transporter 1 (mOAT1). mOAT1 cDNA was obtained from mouse kidney cDNA library and expressed in Xenopus oocytes. mOAT1 mediated sodiumindependent uptake of [^<14>C] p-aminohippurate ([^<14>C] PAH) (Km = 5.92μM). mOAT1-mediated [^<14>C] PAH uptake was inhibited by various organic compounds, including probenecid, indomethacin and furosemide. mOAT1 transported [^3H] ochratoxin A (Km = 1.19μM), [^<14>C] glutarate (2.89μM), [^<14>C] succinate (16.36μM), [^3H] cGMP (19.79μM), [^<14>C] salicylate (43.16μM), [^3H] prostaglandin E2 (70.19μM), [^3H] cimetidine (121.8μM), and [^3H] cAMP (172.4μM). In Northern blot analysis, mOAT1 mRNA was expressed strongly in kidney, and weakly in brain. Immunohistochemical analysis using rabbit polyclonal antibody against the carboxyl-terminal 14 peptides of mOAT1 revealed that mOAT1 was expressed at the basolateral membrane of S2 segment of the proximal tubules. These results indicate that mOAT1 is the mouse paralogue of OAT1 in rats and humans which exist on the basolateral membrane of renal proximal tubules and play an essential role in the tubular excretion of organic anions from kidney.
-
薬学雑誌, 124 25-28, Nov 25, 2004
-
Journal of toxicological sciences, 29(4) 448-448, Oct 29, 2004
-
Journal of toxicological sciences, 29(4) 466-466, Oct 29, 2004
-
Korean Journal of Physiology and Pharmacology, 8(3) 117-127, Jun, 2004
-
TOXICOLOGY AND APPLIED PHARMACOLOGY, 197(3) 297-298, Jun, 2004
-
TOXICOLOGY AND APPLIED PHARMACOLOGY, 197(3) 218-218, Jun, 2004
-
FASEB JOURNAL, 18(8) C280-C280, May, 2004
-
JOURNAL OF UROLOGY, 171(4) 297-297, Apr, 2004
-
FASEB JOURNAL, 18(5) A1250-A1250, Mar, 2004
-
FASEB JOURNAL, 18(4) A695-A695, Mar, 2004
-
FASEB JOURNAL, 18(4) A320-A321, Mar, 2004
-
FASEB JOURNAL, 18(4) A707-A707, Mar, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 138P-138P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 262P-262P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 262P-262P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 127P-127P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 127P-127P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 40P-40P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 242P-242P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 112P-112P, 2004
Books and Other Publications
41Presentations
38Professional Memberships
16Research Projects
54-
科学研究費助成事業, 日本学術振興会, Apr, 2026 - Mar, 2029
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2022
-
Study on the effects of amino acid availability on life span and the underlying molecular mechanismsGrants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Jun, 2018 - Mar, 2020